Outsourcing Pharma
JANUARY 10, 2022
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.
Fierce Healthcare
JANUARY 10, 2022
Investors poured record-breaking $29.1B into digital health startups. Will the momentum continue in 2022? hlandi. Mon, 01/10/2022 - 12:17.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 10, 2022
Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years of effort to bring a drug to market that inhibits KRAS – a cancer target that for a long time was considered “undruggable” The European Commission has approved Lumykras (sotorasib) as a monotherapy for adults with advanced non-small-cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one earlier line of systemic therapy – a use cleared last M
Fierce Healthcare
JANUARY 10, 2022
Facing understaffed hospitals, California temporarily allows asymptomatic workers to return after positive COVID test, exposure. dmuoio. Mon, 01/10/2022 - 13:27.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Impact Pharmaceutical Services
JANUARY 10, 2022
January 10, 2022 | Julia DiFiore, PhD | Clinical Research Scientist I | Regulatory Affairs Many of us involved with drug development derive a lot of satisfaction in knowing that our work contributes to improving the health of patients around the globe. We offer our insight and expertise to design studies, analyze the results, and […].
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: Aledade scoops up advance care planning startup Iris Healthcare to build out health services unit. hlandi. Mon, 01/10/2022 - 20:53.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
JANUARY 10, 2022
Insurers must cover at-home COVID-19 tests starting Jan. 15 under new CMS directive. rking. Mon, 01/10/2022 - 16:18.
pharmaphorum
JANUARY 10, 2022
Swiss biotech Idorsia has claimed FDA approval for its first product – insomnia treatment Quviviq – setting up a market challenge to class rivals from Merck & Co and Eisai. The US regulator has cleared two doses of dual orexin receptor antagonist (DORA) Quviviq (daridorexant) – 25 mg and 50 mg – for the treatment of adults with insomnia characterised by difficulties with falling or staying asleep.
Fierce Healthcare
JANUARY 10, 2022
JPM22: Teladoc projects $2.03B in 2021 revenue, up from previous guidance, after stock plummeted last year. rtorrence. Mon, 01/10/2022 - 10:54.
Pharma Mirror
JANUARY 10, 2022
Speaking, hearing, and comprehending is how most of us communicate with the outside world, and being unable to do so — or even to do so with difficulty — can be a significant impediment to dealing with others. In particular, communications disorders can be a major challenge to school-age children, who might struggle to reach their full potential or even get the most out of their schooling.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: Intermountain Healthcare, SCL Health merger 'will not drive up healthcare costs,' execs promise. dmuoio. Mon, 01/10/2022 - 11:48.
Outsourcing Pharma
JANUARY 10, 2022
Life science investor group, Novo Holdings, has agreed to buy Ritedose, the largest sterile CDMO in the US focused on advanced blow-fill-seal technology, from Hong-Kong based, AGIC Capital, and Chinaâs Humanwell.
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: Staffing expenses led to an extra $440M in operating costs in 2021 for AdventHealth. rking. Mon, 01/10/2022 - 08:43.
Pharma Mirror
JANUARY 10, 2022
Southampton, UK: Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, today announces a partnership with global experts in strategic engagement and commercialisation, Ashfield Engage.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
JANUARY 10, 2022
HHS: Nearly 14M people enroll on ACA's exchanges ahead of Jan. 15 deadline. rking. Mon, 01/10/2022 - 11:41.
pharmaphorum
JANUARY 10, 2022
Regeneron has enlisted the aid of Ultragenyx to add momentum to the rollout of its recently-approved Evkeeza outside the US, which was approved for an inherited form of elevated cholesterol in the US and Europe last year. Regeneron said Ultragenyx’ focus on rare diseases makes it a good match for Evkeeza (evinacumab), as its approved indication – homozygous familial hypercholesterolaemia (HoFH) – which affects around 1,300 people per year in the US.
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: R1 RCM picks up AI software firm Cloudmed in $4.1B all-stock deal. hlandi. Mon, 01/10/2022 - 10:48.
pharmaphorum
JANUARY 10, 2022
Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. The German group is paying $40 million upfront to kick off the alliance, which is focusing on the development of up to five CRISPR drugs that can be delivered in vivo for liver-targeted diseases.
Fierce Healthcare
JANUARY 10, 2022
There were fewer M&A transactions in 2021, but they were greater in size: analysis. agliadkovskaya. Mon, 01/10/2022 - 15:53.
Outsourcing Pharma
JANUARY 10, 2022
Checking in with pharma executives, the survey outlines leadersâ thoughts about current and future challenges, like costs, security, and inventory control.
Fierce Healthcare
JANUARY 10, 2022
Aduhelm price drops prompts Becerra to rethink hike to Part B 2022 premiums. rking. Mon, 01/10/2022 - 10:44.
Outsourcing Pharma
JANUARY 10, 2022
The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: Humana execs try to soothe skittish investors as new MA enrollment projections disappoint. pminemyer. Mon, 01/10/2022 - 16:21.
Pharma Times
JANUARY 10, 2022
The chronic, inflammatory disease affects an estimated 24 in every 10,000 people.
Fierce Healthcare
JANUARY 10, 2022
JPM 2022: Centene execs tout strong MA enrollment period—though work remains on star scores. pminemyer. Mon, 01/10/2022 - 10:31.
Pharma Times
JANUARY 10, 2022
Since April 2021, around 84,000 pregnant women have received at least one COVID-19 vaccination.
Fierce Healthcare
JANUARY 10, 2022
Vista Equity Partners invests in healthcare communication software company TigerConnect. rtorrence. Mon, 01/10/2022 - 17:00.
pharmaphorum
JANUARY 10, 2022
The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Ben Hargreaves takes a look at how the space is currently progressing and in what direction it could be heading in future. The pandemic brought about an interesting phenomenon for the pharmaceutical industry: there is a much greater awareness of both individual companies within the industry and their individua
pharmaphorum
JANUARY 10, 2022
There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an antiviral drug developed by Molecular Partners. The opt-in has been prompted by the results of a phase 2 trial of ensovibep (MPO420), which showed that a single intravenous dose of the drug was able to not only reduce viral load in non-hospitalised COVID-19 patients over eight days, but also cut the risk of hospitalisation or death by 78% versus placebo.
Expert insights. Personalized for you.
136 
Let's personalize your content